Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury

Launched by UNIVERSITY OF MANITOBA · Nov 20, 2012

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to reduce blood loss during surgery for burn injuries. Typically, doctors use a solution containing epinephrine, which can sometimes cause side effects like increased heart rate and blood pressure. In this trial, researchers will use phenylephrine instead, as they believe it will help control blood loss without affecting the heart or blood pressure. The participants will receive an injection of the phenylephrine solution under the skin where the burn is located, and then they will undergo a skin graft, similar to the usual procedure.

To be eligible for this trial, participants need to have a burn injury that requires treatment involving skin removal and grafting, covering about 5% to 30% of their body surface area. However, those with burns on the head, neck, hands, feet, or genitals, or those taking certain medications or with specific health conditions, may not qualify. If you participate, you can expect to receive the phenylephrine injection and undergo standard care for your burn, while helping researchers understand its effectiveness in reducing blood loss during surgery.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • a) Burn injury requiring debridement and grafting between 5-30% TBSA
• • Exclusion Criteria
• • 1. Head and neck, hand, foot, or genital burns
• • 2. On anticoagulants (except NSAIDs)
• • 3. On monoamine oxidase inhibitor or tricyclic antidepressant
• • 4. Coronary or peripheral vascular disease
• • 5. History of arrhythmias
• • 6. On a Beta-blocker
• • 7. History of vascular abnormality
• • 8. Hypertension